DK2486924T3 - Lægemidler og anvendelser - Google Patents
Lægemidler og anvendelser Download PDFInfo
- Publication number
- DK2486924T3 DK2486924T3 DK12167186.1T DK12167186T DK2486924T3 DK 2486924 T3 DK2486924 T3 DK 2486924T3 DK 12167186 T DK12167186 T DK 12167186T DK 2486924 T3 DK2486924 T3 DK 2486924T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- ene
- cells
- compounds
- animals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Forbindelse til anvendelse i profylaksen eller behandlingen afen stofskiftesygdom eller -tilstand, en knogletabstilstand eller smerte, hvor forbindelsen er 17a-ethynylandrost-5-en-3p, 7β, 17β-ίποΙ, eller en C2-4-monoester eller C2-4-diester analog af denne forbindelse, eventuelt hvor monoesteren er acetat i 3- eller 17-positionen eller diesteren er acetat i 3- og 17-positionen.
2. Forbindelse til anvendelse ifølge krav 1 i profylaksen eller behandlingen afen stofskiftesygdom eller -tilstand.
3. Forbindelse til anvendelse ifølge krav 2, hvor forbindelsen er 17a- ethynylandrost-5-en-36, 7β, 17β-ίποΙ.
4. Forbindelse til anvendelse ifølge krav 3, hvor stofskiftesygdommen eller -tilstanden er type-2-diabetes.
5. Forbindelse til anvendelse ifølge krav 3, hvor stofskiftesygdommen eller -tilstanden er hyperglykæmi.
6. Forbindelse til anvendelse ifølge krav 3, hvor stofskiftesygdommen eller -tilstanden er type-l-diabetes.
7. Forbindelse til anvendelse ifølge krav 3, hvor stofskiftesygdommen eller -tilstanden er insulinresistens, fedme, arteriosklerose, hypertension, metabolsk syndrom eller en hyperlipidæmisk tilstand.
8. Forbindelse til anvendelse ifølge krav 1 i profylaksen eller behandlingen af smerte.
9. Forbindelse til anvendelse ifølge krav 8, hvor forbindelsen er 17a- ethynylandrost-5-en-36, 7β, 17β-ίποΙ.
10. Forbindelse til anvendelse ifølge krav 9, hvor smerten er ledsmerte eller er smerte associeret med kræft.
11. Forbindelse til anvendelse ifølge krav 1 i profylaksen eller behandlingen afen knogletabstilstand, hvor knogletabstilstanden er osteoporose eller et knoglebrud, eller et knogletab associeret med et termisk, stråle- eller kemisk forbrænding, tilstedeværelsen af forhøjede niveauer af naturlig glukokotikoid eller tilstedeværelsen af et syntetisk glukokotikoid.
12. Forbindelse til anvendelse ifølge krav 11, hvor forbindelsen er 17a-ethynylandrost-5-en-3p, 7β, 17β-ίποΙ.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79379206P | 2006-04-22 | 2006-04-22 | |
US84311206P | 2006-09-08 | 2006-09-08 | |
US82556906P | 2006-09-13 | 2006-09-13 | |
US82556406P | 2006-09-13 | 2006-09-13 | |
US82984806P | 2006-10-17 | 2006-10-17 | |
US86639506P | 2006-11-17 | 2006-11-17 | |
US86670006P | 2006-11-21 | 2006-11-21 | |
US86804206P | 2006-11-30 | 2006-11-30 | |
US88500307P | 2007-01-15 | 2007-01-15 | |
US88805807P | 2007-02-02 | 2007-02-02 | |
EP07863339A EP2012773B1 (en) | 2006-04-22 | 2007-04-23 | Drugs and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2486924T3 true DK2486924T3 (da) | 2019-03-04 |
Family
ID=39230844
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12167186.1T DK2486924T3 (da) | 2006-04-22 | 2007-04-23 | Lægemidler og anvendelser |
DK07863339.3T DK2012773T3 (da) | 2006-04-22 | 2007-04-23 | Lægemidler og anvendelser deraf |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07863339.3T DK2012773T3 (da) | 2006-04-22 | 2007-04-23 | Lægemidler og anvendelser deraf |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP2012773B1 (da) |
JP (2) | JP5130591B2 (da) |
KR (1) | KR20080112413A (da) |
CN (1) | CN103211821A (da) |
AU (2) | AU2007300404B2 (da) |
CA (1) | CA2649940C (da) |
DK (2) | DK2486924T3 (da) |
EA (1) | EA200802167A1 (da) |
ES (2) | ES2389743T3 (da) |
HU (1) | HUE042925T2 (da) |
IL (1) | IL194751A0 (da) |
PL (2) | PL2486924T3 (da) |
WO (1) | WO2008039566A2 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
US8354396B2 (en) | 2006-11-17 | 2013-01-15 | Harbor Therapeutics, Inc. | Drug identification and treatment method |
US8217025B2 (en) | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
US8486926B2 (en) | 2006-11-17 | 2013-07-16 | Harbor Therapeutics, Inc. | Steroid tetrol solid state forms |
CN101939009B (zh) * | 2008-02-05 | 2013-07-17 | 哈博生物科学公司 | 药学固体形式 |
PT2273994E (pt) | 2008-04-03 | 2016-03-15 | Neurmedix Inc | Formas de estado sólido de um produto farmacêutico |
DK2300489T3 (da) * | 2008-06-06 | 2016-02-15 | Neurmedix Inc | Fremgangsmåder til fremstilling af 17-alkynyl-7-hydroxy-steroider og relaterede forbindelser |
US20130217749A1 (en) * | 2010-06-10 | 2013-08-22 | Yale University | Modulation of phosphoenolpyruvate carboxykinase-mitchondrial (pepck-m) expression |
CN103402523A (zh) * | 2010-12-17 | 2013-11-20 | 哈博生物科学公司 | 甾族化合物四醇固体形式-2 |
CN107936076B (zh) * | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
ITMI20121472A1 (it) * | 2012-09-04 | 2014-03-05 | Ind Chimica Srl | Processo per la preparazione di 11-metilen-18-metilestr-4-en-3,17-dione, utile come intermedio per la sintesi di molecole ad attivita' farmacologica |
KR101687061B1 (ko) * | 2014-02-25 | 2016-12-16 | 순천향대학교 산학협력단 | 나이에 따른 당뇨병 진단을 위한 글루코코르티코이드 수용체의 검출제제를 포함하는 타입 2 당뇨 진단 키트 |
CN105017361A (zh) * | 2015-07-16 | 2015-11-04 | 湖北竹溪人福药业有限责任公司 | 一种去氢表雄酮的合成方法 |
CN113350359B (zh) | 2017-12-29 | 2022-08-16 | 广州市赛普特医药科技股份有限公司 | 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用 |
CN109369760B (zh) * | 2018-12-18 | 2021-01-01 | 湖南科瑞生物制药股份有限公司 | 一种制备去氢甲基睾丸素的方法 |
CN109369761B (zh) * | 2018-12-18 | 2021-01-01 | 湖南科瑞生物制药股份有限公司 | 一种去氢甲基睾丸素的制备方法 |
CN113318114B (zh) * | 2020-02-28 | 2023-02-17 | 广州市赛普特医药科技股份有限公司 | 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途 |
CN114195844B (zh) * | 2021-12-29 | 2023-03-17 | 湖北武当安泰药业有限公司 | 一种去氢表雄酮的制备方法 |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
US4898694A (en) * | 1987-11-25 | 1990-02-06 | Schwartz Arthur G | 17-Hydroxy-steroids |
AU7978794A (en) * | 1993-10-13 | 1995-05-04 | Neurocrine Biosciences, Inc. | 3,17-dihydroxy-3,7,16 and/or 17-methyl-androst-5-ene compounds, derivatives thereof, and their use |
US6545027B1 (en) | 1995-06-07 | 2003-04-08 | Eli Lilly And Company | Methods of modulating NF-kB transcription factor |
US5989835A (en) | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
US5753266A (en) * | 1996-12-03 | 1998-05-19 | Youssefyeh; Parvin | Safflower seed powder compositions for the treatment of rheumatoid based arthritic diseases |
US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
AU2005211675B2 (en) * | 1999-03-23 | 2009-09-24 | Harbor Biosciences, Inc. | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone |
EP1422234A3 (en) * | 1999-03-23 | 2010-12-08 | Harbor BioSciences, Inc. | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone |
AU6444600A (en) * | 1999-08-06 | 2001-03-05 | Glaxo Wellcome S.A. | New protein |
EP2322182A1 (en) * | 1999-09-30 | 2011-05-18 | Harbor BioSciences, Inc. | Androstenol derivatives as androgen receptor modulator |
US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
US6593511B1 (en) | 2000-05-12 | 2003-07-15 | Bioseek, Inc. | Models of chronic and acute inflammatory diseases |
AU2002244247B2 (en) * | 2001-03-01 | 2007-12-13 | Harbor Biosciences, Inc. | Use of certain steroids for treatment of blood cell deficiencies |
CA2447431A1 (en) | 2001-05-11 | 2002-11-21 | Research Development Foundation | Inhibitors of receptor activator of nf-kb and uses thereof |
AU2002340119A1 (en) * | 2001-10-09 | 2003-04-22 | Immunex Corporation | Mammalian c-type lectins |
AU2003278744B2 (en) * | 2002-08-28 | 2010-07-29 | Harbor Biosciences, Inc. | Therapeutic treatment methods |
WO2004043986A1 (en) * | 2002-11-07 | 2004-05-27 | Pharmacia & Upjohn Company Llc | Processes for preparing c-7 substituted 5-androstenes |
US7884196B2 (en) | 2004-10-06 | 2011-02-08 | Oliver Lawless | Vaccine composition comprising methylated DNA and immunomodulatory motifs |
-
2007
- 2007-04-23 CN CN2013100543094A patent/CN103211821A/zh active Pending
- 2007-04-23 EP EP07863339A patent/EP2012773B1/en active Active
- 2007-04-23 PL PL12167186T patent/PL2486924T3/pl unknown
- 2007-04-23 ES ES07863339T patent/ES2389743T3/es active Active
- 2007-04-23 PL PL07863339T patent/PL2012773T3/pl unknown
- 2007-04-23 ES ES12167186T patent/ES2710288T3/es active Active
- 2007-04-23 DK DK12167186.1T patent/DK2486924T3/da active
- 2007-04-23 EA EA200802167A patent/EA200802167A1/ru unknown
- 2007-04-23 EP EP12167186.1A patent/EP2486924B1/en active Active
- 2007-04-23 JP JP2009506814A patent/JP5130591B2/ja active Active
- 2007-04-23 DK DK07863339.3T patent/DK2012773T3/da active
- 2007-04-23 CA CA2649940A patent/CA2649940C/en active Active
- 2007-04-23 AU AU2007300404A patent/AU2007300404B2/en active Active
- 2007-04-23 HU HUE12167186A patent/HUE042925T2/hu unknown
- 2007-04-23 KR KR1020087028733A patent/KR20080112413A/ko not_active Application Discontinuation
- 2007-04-23 WO PCT/US2007/067235 patent/WO2008039566A2/en active Application Filing
-
2008
- 2008-10-22 IL IL194751A patent/IL194751A0/en unknown
-
2010
- 2010-03-17 AU AU2010201023A patent/AU2010201023B2/en active Active
-
2012
- 2012-09-27 JP JP2012214102A patent/JP2012255033A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2012773A2 (en) | 2009-01-14 |
AU2007300404B2 (en) | 2009-12-17 |
EP2486924B1 (en) | 2018-12-26 |
WO2008039566A2 (en) | 2008-04-03 |
EP2012773B1 (en) | 2012-06-20 |
ES2710288T3 (es) | 2019-04-24 |
CA2649940C (en) | 2012-08-07 |
AU2010201023B2 (en) | 2012-02-09 |
EP2012773A4 (en) | 2010-01-13 |
DK2012773T3 (da) | 2012-09-24 |
ES2389743T3 (es) | 2012-10-31 |
WO2008039566A3 (en) | 2008-11-27 |
IL194751A0 (en) | 2009-08-03 |
KR20080112413A (ko) | 2008-12-24 |
AU2010201023A1 (en) | 2010-04-08 |
EA200802167A1 (ru) | 2009-04-28 |
PL2486924T3 (pl) | 2019-07-31 |
AU2007300404A1 (en) | 2008-04-03 |
CA2649940A1 (en) | 2008-04-03 |
HUE042925T2 (hu) | 2019-07-29 |
EP2486924A3 (en) | 2013-01-09 |
PL2012773T3 (pl) | 2012-12-31 |
CN103211821A (zh) | 2013-07-24 |
JP2009534427A (ja) | 2009-09-24 |
JP2012255033A (ja) | 2012-12-27 |
EP2486924A2 (en) | 2012-08-15 |
JP5130591B2 (ja) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2486924T3 (da) | Lægemidler og anvendelser | |
US8354396B2 (en) | Drug identification and treatment method | |
US8217025B2 (en) | Drug screening and treatment methods | |
US20080221074A1 (en) | Drug Screen and Treatment Method | |
US20080153792A1 (en) | Drug Identification and Treatment Method | |
CA2774197A1 (en) | Drugs and uses to modulate inflammation, metabolic disorders and other conditions | |
US8486926B2 (en) | Steroid tetrol solid state forms | |
Huang et al. | A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage | |
Duddempudi | Immunology in alcoholic liver disease | |
Chen et al. | Short chain fatty acids inhibit endotoxin-induced uveitis and inflammatory responses of retinal astrocytes | |
Yu et al. | Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in Gulo (−/−) mice | |
Ahlem et al. | Pharmacology and immune modulating properties of 5-androstene-3β, 7β, 17β-triol, a DHEA metabolite in the human metabolome | |
US20210030757A1 (en) | Method of treatment and compositions comprising a dual p13k delta-gamma kinase inhibitor and a corticosteroid | |
Ezeamuzie et al. | Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251)–A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation | |
WO2017209270A1 (ja) | 25-ヒドロキシコレステロール又はその類縁体コレステロールを有効成分として含有してなる、活性化されたt細胞及び/又はb細胞に選択的な細胞死誘導剤又は細胞死促進剤 | |
Halima | Ginsenosides as selecti e glucocorticoid drugs: agonists, antagonists, and prodrugs | |
Pastwinska et al. | BBA-Reviews on Cancer | |
Williams | Articles in PresS. Am J Physiol Gastrointest Liver Physiol (August 7, 2014). doi: 10.1152/ajpgi. 00163.2014 | |
Shimp III | Inhibition of Heat Shock Protein 90 Reduces Inflammatory Signal Transduction in Murine J774 Macrophage Cells and Lessens Disease in Autoimmune MRL/lpr Mice: What in vitro, in vivo, and in silico Models Reveal |